Noninvasive Fecal IgA Food Sensitivity Diagnostic Test
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying chronic immunological food sensitivities are invasive, expensive, and often ineffective, leading to unnoticed reactions that can cause prolonged health issues and complicate disease management.
Innovation Solution
A noninvasive food sensitivity testing system using a fecal sample collection kit with antibody binding agents on a substrate, allowing for the identification of food sensitivities through IgA antibodies present in the fecal sample, providing a visual indication of sensitivity via flag changes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If scratch tests and blood tests are used to identify food sensitivities, then diagnostic accuracy may be improved, but patient discomfort and cost increase
Solution Approach 1:
The patent extracts the diagnostic function from invasive procedures (scratch tests, blood tests) and relocates it to a noninvasive fecal sample-based test. The antibody binding agents are coupled to a substrate that contacts fecal samples, allowing detection of IgA antibodies associated with food sensitivities without requiring skin penetration or blood withdrawal.
Solution Approach 2:
The patent introduces an intermediary substance (antibody binding agent) that mediates between the fecal sample containing IgA antibodies and the diagnostic detection system. The antibody binding agent couples with the IgA antibodies in the fecal sample and transfers them to the test region, enabling indirect detection that avoids direct patient discomfort while maintaining diagnostic capability.
2Loss of information
If elimination diets are used to identify food sensitivities, then diagnostic information may be obtained, but unnecessary calorie restriction and nutritional deficiencies occur
Solution Approach 1:
The patent performs preliminary diagnostic action through fecal sample testing before implementing any dietary restrictions. By detecting IgA antibodies associated with specific food sensitivities in advance, the system provides definitive information about which foods to eliminate, preventing unnecessary elimination of nutritious foods and avoiding calorie restriction and nutritional deficiencies.
3Measurement precision
If traditional diagnostic methods are used, then comprehensive testing may be performed, but device complexity and cost increase
Solution Approach 1:
The patent segments the diagnostic system into simple, discrete components: a substrate with coupled antibody binding agents, a fecal sample collection mechanism, and visual indication elements (flags). This segmentation allows the complex diagnostic function to be performed through simple, separate steps that reduce overall system complexity and make the test more accessible.
4Object-affected harmful factors
If fecal sample testing is implemented, then noninvasive diagnosis is achieved, but sample collection difficulty may increase
Solution Approach 1:
The patent enables self-service sample collection by providing a fecal collection device that patients can use independently at home. The device includes a collection container and integrated testing components, allowing patients to collect fecal samples and perform testing themselves without requiring clinical staff assistance, thereby maintaining noninvasiveness while improving operational ease.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system allows for accurate and cost-effective identification of food sensitivities, reducing patient discomfort and unnecessary calorie restriction, while aiding in diagnosing associated diseases and disorders.
Implementation Method 1
The antibody binding agent(s) may couple with first antibodies, associated with one or more of the foods sensitivities in the first set of food sensitivities, when the first antibodies are present in a fecal sample obtained from the human
Implementation Method 2
The absorbent region may contact the fecal sample and absorbs fluid from the fecal sample to transfer to the test region
Data Source
Figure 1A
Figure 1B
Figure 2
AI summary
In various implementations, a noninvasive, food sensitivity test may be utilized to identify one or more food sensitivities. A fecal sample may be obtained. The food sensitivity test may be performed on the obtained fecal sample. One or more food sensitivities may be identified based on the food sensitivity test.